B

Bravis Ziekenhuis | Roosendaal - Cardiology Department

Research site
(Unclaimed)
Location
Boerhaavelaan 25, Roosendaal, Noord-Brabant, Netherlands

Site insights

Top conditions

Top treatments

Semaglutide
Atezolizumab
Ribociclib
Bevacizumab
Dapagliflozin
Olaparib
Fulvestrant
panitumumab
Panitumumab
Durvalumab

Parent organization

This site is a part of Bravis Ziekenhuis

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 31 total trials

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL (EPCORE DLBCL-1)

The purpose of this trial is to find out if epcoritamab, also known as EPKINLY™ and GEN3013, is safe and works well as treatment for patients with di...

Active, not recruiting
Diffuse Large B-cell Lymphoma
Drug: Investigator's Choice Chemotherapy
Biological: Epcoritamab

This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 s...

Active, not recruiting
Obesity
Drug: Semaglutide
Drug: Placebo semaglutide

The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivek...

Begins enrollment this month
Acute Myocardial Infarction (AMI)
Cardiovascular Risk
Drug: Placebo
Drug: Ziltivekimab

Digoxin is the oldest, market-authorized drug for heart failure (HF), and very cheap. A large trial with digoxin, the DIG trial, executed in the earl...

Active, not recruiting
Heart Failure
Drug: Digoxin
Drug: Placebos
Locations recently updated

This study will randomize patients recently discharged from the hospital with a confirmed diagnosis of type 1 acute myocardial infarction (Thygesen e...

Invitation-only
Acute Myocardial Infarction
Combination Product: Placebo
Combination Product: Selatogrel

This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare pirtobrutinib (LOXO-30...

Active, not recruiting
Lymphoma, Mantle-Cell
Drug: Ibrutinib
Drug: Pirtobrutinib

The aim of this prospective, randomized, multicenter, open-label, phase II study is to test if chemotherapy can be replaced by the combination of rib...

Active, not recruiting
Breast Neoplasms
Drug: Chemotherapy
Drug: Letrozole

This is a prospective, non-randomized clinical trial that aims to describe the efficacy and toxicity of commercially available, targeted anticancer d...

Enrolling
Tumors
Neoplasm
Drug: Tepotinib
Drug: Axitinib

Rationale:Sodium glucose co transporter 2 (SGLT2) inhibitors are a relatively new class of agents, originally developed as oral antihyperglycemic dru...

Invitation-only
Kidney Failure
Death
Drug: Dapagliflozin 10 mg/day (oral)
Drug: Placebo

Triple negative breast cancer (TNBC) is a difficult to treat molecular subtype with a poor survival. TNBC can be divided into at least two molecular...

Active, not recruiting
Breast Cancer
Drug: Paclitaxel
Drug: Carbo/cyclo + atezolizumab

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with...

Enrolling
Chronic Kidney Disease
Inflammation
Drug: Placebo (Ziltivekimab B)
Drug: Placebo (Ziltivekimab C)

Trial sponsors

Novo Nordisk logo
R
U
Bayer logo
Netherlands Cancer Institute (NKI) logo
B
D
Genmab logo
Idorsia Pharmaceuticals logo
L

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems